New group clinical transformation director appointed
Congratulations to Dr Neil Ashman, who has been appointed to the important new group role of clinical transformation director for Barts Health.
This is a new post on the group executive board, and a testament to our commitment to achieving sustainable change that improves health services and health outcomes for all our patients.
Neil will provide overall clinical leadership for our six priority transformation programmes in elective care, pathway redesign, medicine, patient safety, diagnostics and urgent and emergency care.
These programmes are seeking to do things differently so we can improve outcomes, reduce inequalities and increase equity, while also driving efficiency and productivity as we cater for ever-greater demand.
Neil is a consultant nephrologist (kidney expert) at The Royal London hospital and has held a variety of key posts in recent years. He was formerly deputy chief executive at RLH, and most currently chairs the medicine clinical board and leads the group’s outpatient transformation programme.
In his new role Neil will work closely with Prof Alistair Chesser, our group chief medical officer, in co-ordinating the work of our nine clinical boards and shaping our over-arching clinical strategy as we emerge from the crisis phase if the pandemic.
Neil will also lead an informal clinical transformation network of senior leaders that includes our director of development, Prof Louise Hicks; our director of quality improvement, Dr Chris Gordon; our director of public health, Dr Ian Basnett; and our chief clinical information officer, Dr Charles Gutteridge.
Prof Chesser said: “Neil has great medical experience and a proven track record of clinical leadership, so on behalf of the group executive I am delighted to welcome him to this new role. We have an opportunity to ensure that our recovery from Covid is achieved in a genuinely transformative way that not only meets the continuing needs of our patients but also sets us up for the future. Our challenge is to develop a post-pandemic clinical strategy that improves both the quality of our care and our productivity in the best interests of our staff and patients.”